- Home
- PBYI vs FHTX Comparison
PBYI vs FHTX Comparison
Compare PBYI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- FHTX
- Stock Information
- Founded
- PBYI 2010
- FHTX 2015
- Country
- PBYI United States
- FHTX United States
- Employees
- PBYI N/A
- FHTX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- PBYI Health Care
- FHTX Health Care
- Exchange
- PBYI Nasdaq
- FHTX Nasdaq
- Market Cap
- PBYI 237.2M
- FHTX 278.1M
- IPO Year
- PBYI N/A
- FHTX 2020
- Fundamental
- Price
- PBYI $5.41
- FHTX $4.31
- Analyst Decision
- PBYI Strong Buy
- FHTX Strong Buy
- Analyst Count
- PBYI 1
- FHTX 5
- Target Price
- PBYI $7.00
- FHTX $11.80
- AVG Volume (30 Days)
- PBYI 511.9K
- FHTX 169.1K
- Earning Date
- PBYI 11-06-2025
- FHTX 11-03-2025
- Dividend Yield
- PBYI N/A
- FHTX N/A
- EPS Growth
- PBYI 434.29
- FHTX N/A
- EPS
- PBYI 0.97
- FHTX N/A
- Revenue
- PBYI $238,062,000.00
- FHTX $24,173,000.00
- Revenue This Year
- PBYI N/A
- FHTX $43.75
- Revenue Next Year
- PBYI N/A
- FHTX $1.27
- P/E Ratio
- PBYI $5.56
- FHTX N/A
- Revenue Growth
- PBYI 8.63
- FHTX N/A
- 52 Week Low
- PBYI $2.32
- FHTX $2.95
- 52 Week High
- PBYI $6.07
- FHTX $9.70
- Technical
- Relative Strength Index (RSI)
- PBYI 65.34
- FHTX 40.21
- Support Level
- PBYI $5.11
- FHTX $4.03
- Resistance Level
- PBYI $5.42
- FHTX $4.84
- Average True Range (ATR)
- PBYI 0.25
- FHTX 0.33
- MACD
- PBYI 0.06
- FHTX -0.02
- Stochastic Oscillator
- PBYI 75.36
- FHTX 25.57
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.